Which two injections are being compared?
The weight loss injection landscape is dominated by two active molecules — semaglutide and tirzepatide. Both require a prescription, both are administered as once-weekly subcutaneous injections, and both achieve weight management through overlapping but distinct mechanisms.
Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a naturally occurring hormone that regulates appetite and slows gastric emptying. The net effect is reduced calorie intake driven by earlier satiety and reduced hunger.
Tirzepatide is a dual agonist — it activates both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. GIP is another gut-derived hormone that affects energy balance and fat metabolism. The dual-pathway activation is the reason tirzepatide generally produces greater weight reduction in head-to-head data.
What does the efficacy data show?
Semaglutide (STEP 1)
The STEP 1 trial (New England Journal of Medicine, 2021) randomized 1,961 adults with overweight or obesity to semaglutide 2.4 mg once weekly versus placebo over 68 weeks. Results at 68 weeks:
- Mean body weight reduction: 14.9% with semaglutide vs. 2.4% with placebo.
- 86% of participants lost at least 5% body weight.
- 32% lost at least 20% body weight.
These are substantial results by any standard. Semaglutide represented a meaningful step beyond older GLP-1 medications.
Tirzepatide (SURMOUNT-1)
The SURMOUNT-1 trial (New England Journal of Medicine, 2022) randomized 2,539 adults with obesity to tirzepatide (5, 10, or 15 mg) versus placebo over 72 weeks. At the highest dose (15 mg):
- Mean body weight reduction: 20.9% — approximately 6 percentage points more than semaglutide in STEP 1.
- 91% of participants lost at least 5% body weight.
- 57% lost at least 20% body weight — nearly double the semaglutide rate.
Comparing across separate trials has limitations (different populations, trial designs, timeframes). The SURPASS-6 head-to-head trial confirmed tirzepatide’s advantage in a direct comparison population, though the margin varies by individual.
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 agonist | Dual GLP-1 + GIP agonist |
| Average weight loss (key trial) | ~14.9% body weight (STEP 1, 68 wks) | ~20.9% body weight (SURMOUNT-1, 72 wks) |
| Participants losing ≥20% | 32% | 57% |
| Dosing | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection |
| Main GI side effects | Nausea, constipation, diarrhea | Nausea, constipation, diarrhea |
| Compounded formulation | Available (not FDA-approved drug) | Available (not FDA-approved drug) |
Tirzepatide wins on average weight loss in the trials — but the best injection for you is the one you can tolerate and stay on at an effective dose.
How do the side effects of semaglutide and tirzepatide compare?
Both medications share the same core GI side-effect profile because both activate the GLP-1 pathway:
- Nausea (most common, typically peaks early in titration)
- Vomiting
- Constipation or diarrhea
- Decreased appetite (often the point, but can be too much)
- Injection-site reactions
In the trials, GI adverse event rates were broadly similar between the two compounds. Some patients find one tolerable and the other less so — this is individual and difficult to predict in advance. The slow titration protocol is the single most effective mitigation for both medications.
The rare but serious risks — pancreatitis, gallbladder events — exist for both and should be reviewed with your clinician before starting either.
How does a clinician decide which weight loss injection is right for you?
No injection is objectively “the best” across all patients. A clinician will weigh:
- Degree of weight reduction goal: Patients targeting significant reduction (>15% body weight) are often better served by tirzepatide based on trial data. Patients targeting moderate reduction may achieve excellent results with semaglutide.
- Medical history: Contraindications (history of pancreatitis, MEN2, medullary thyroid carcinoma personal or family history) rule out both. Other conditions may influence the choice.
- Current medications: Potential interactions affect the selection.
- Prior response: Patients who tolerated semaglutide well but want to explore greater efficacy may transition to tirzepatide. The reverse is also possible.
- Individual tolerability: Side-effect response is the primary reason for switching in practice.
Are compounded versions the same as the branded drugs?
Branded semaglutide (Ozempic, Wegovy) and branded tirzepatide (Mounjaro, Zepbound) are FDA-approved prescription medications. Compounded semaglutide and tirzepatide use the same active molecule but are not FDA-approved drugs — they are compounded by licensed pharmacies under a clinician’s prescription. Never compare a compounded product to a branded drug by name or claim identical regulatory status.
PepScribe works exclusively with licensed 503A compounding pharmacies in the USA. No hidden overseas supply chain, no gray-market sourcing. A clinician reviews every patient before prescribing.
So which weight loss injection is best?
If the question is strictly about average weight reduction in clinical trials, tirzepatide’s dual GLP-1/GIP mechanism produces greater results at maximum doses. If the question is which weight loss injection is best for a specific person, that requires a clinician evaluation — medical history, goals, tolerability, and medication context all matter.
The right injection is the one you can stay on at a dose that moves the needle, with side effects you can manage. That determination is clinical, not self-administered.
Frequently asked questions
Which weight loss injection is the best overall?
Head-to-head data (SURPASS-6 and the SURMOUNT-vs-STEP comparison) consistently shows tirzepatide produces greater average weight reduction — approximately 20–22% vs. 15% of body weight with semaglutide at maximum doses over 72 weeks. However, individual response varies; semaglutide may suit patients with different side-effect tolerability or medical history. A clinician review determines the right fit.
What is the difference between semaglutide and tirzepatide?
Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GLP-1 / GIP receptor agonist — it activates both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) pathways simultaneously. The dual mechanism is believed to account for tirzepatide's larger average weight reduction in trials.
Is tirzepatide better than semaglutide for weight loss?
At maximum doses in large randomized trials, tirzepatide produces greater average weight reduction. That said, "better" depends on individual factors including medical history, medications, side-effect tolerance, and goals. Some patients achieve excellent outcomes on semaglutide alone.
Are compounded semaglutide and tirzepatide the same as the branded drug?
The active molecule is the same. Compounded formulations are not FDA-approved drugs; they are prepared by licensed compounding pharmacies and require a clinician's prescription. Product quality depends on the pharmacy. PepScribe uses only licensed 503A compounding pharmacies in the USA — no hidden overseas supply chain.
What weight loss injection has the fewest side effects?
Both semaglutide and tirzepatide share a similar GI side-effect profile (nausea, constipation, diarrhea) because both activate the GLP-1 pathway. Tirzepatide's slightly different receptor profile may affect the nuance of side effects for some patients. A slow titration schedule is the most effective strategy regardless of which medication is chosen.